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Abstract
Objective—To better understand why HIV incidence is substantially higher among black than 
white men who have sex with men (MSM), we present the first nationally representative estimates 
of factors that contribute to transmission – sexual behavior, antiretroviral therapy (ART) use, and 
viral suppression – among HIV-infected black and white MSM in the United States.
Design—The Medical Monitoring Project (MMP) is a complex sample survey of HIV-infected 
adults receiving medical care in the United States.
Methods—We used weighted interview and medical record data collected during June 2009 to 
May 2010 to estimate the prevalence of sexual behaviors, ART use, and viral suppression among 
sexually active HIV-infected black and white MSM. We used χ2 tests to assess significant 
differences between races and logistic regression models to identify factors that mediated the 
racial differences.
Results—Sexual risk behaviors among black and white MSM were similar. Black MSM were 
significantly less likely than white MSM to take ART (80 vs. 91%) and be durably virally 
suppressed (48 vs. 69%). Accounting for mediators (e.g. age, insurance, poverty, education, time 
since diagnosis, and disease stage) reduced, but did not eliminate, disparities in ART use and 
rendered differences in viral suppression among those on ART insignificant.
Conclusion—Lower levels of ART use and viral suppression among HIV-infected black MSM 
may increase the likelihood of HIV transmission. Addressing the patient-level factors and 
structural inequalities that contribute to lower levels of ART use and viral suppression among this 
group will improve clinical outcomes and might reduce racial disparities in HIV incidence.
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Introduction
In the United States, black men who have sex with men (MSM) are disproportionately 
affected by HIV. The rate of new HIV diagnoses among black MSM is six times that among 
white MSM, and black MSM are almost four times as likely to be living with HIV [1]. The 
factors among HIV-infected MSM that may contribute to higher HIV incidence among HIV-
uninfected black MSM are not completely understood. Because black MSM have a high 
probability of choosing other black MSM as partners [2–5], factors that increase the 
probability of transmission from HIV-infected black MSM to their partners also increase 
HIV incidence among HIV-uninfected black MSM. Previous studies have not found 
substantial differences in sexual transmission risk behaviors among black vs. white MSM 
[6–11]. However, the higher HIV prevalence among black MSM means that despite having 
similar or lower numbers of sex partners, HIV-uninfected black MSM are more likely to 
have an HIV-infected same-race partner and are, thus, at increased risk of exposure to HIV 
[12,13].
In addition, lower use of antiretroviral therapy (ART) and, thus, lower levels of viral 
suppression among HIV-infected black MSM might also contribute to increased HIV 
transmission [9,14]. The landmark results of the HIV Prevention Trials Network 052 study 
confirmed that among serodiscordant couples (most of whom were heterosexual), ART use 
resulting in viral suppression sharply reduces the probability of HIV transmission to 
uninfected partners [15]. Most [8,10,16–18], though not all [13,19], studies have 
documented significantly lower ART use among black HIV-infected MSM. However, the 
samples in all of these studies were small or nonrepresentative. Further, only Kelley et al. 
[13] examined viral suppression, which is the direct link between ART use and risk of HIV 
transmission. They found lower levels of viral suppression among black vs. white HIV-
infected MSM in Atlanta, but the difference was not statistically significant. A recent meta-
analysis by Millett et al. [9] used unpublished data from three studies (one of which is the 
source of the data presented in our analysis) to document decreased odds of viral 
suppression among black compared with white MSM. Improving our understanding of the 
differences in viral suppression among US black and white MSM is a first step toward 
assessing ‘treatment as prevention’ [20] as a tool for reducing racial disparities in incidence 
among MSM.
We present the first examination of nationally representative data on the characteristics of 
HIV-infected black and white MSM that may contribute to racial disparities in HIV 
transmission and, thus, help explain some of the racial disparities in HIV incidence. 
Specifically, we present estimates of sexual risk behavior, ART use, and viral suppression 
among sexually active HIV-infected black and white MSM receiving medical care in the 
United States.
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Medical Monitoring Project design and data collection
The Medical Monitoring Project (MMP) is a supplemental HIV surveillance system 
designed to produce nationally representative estimates of behavioral and clinical 
characteristics of HIV-infected adults receiving medical care in the United States [21–23]. 
MMP is a complex-sample, cross-sectional survey. For the 2009 data collection cycle, US 
states and territories were sampled first, followed by facilities providing HIV care, and then 
by HIV-infected adults (persons aged 18 years and older) who had at least one medical care 
visit during January to April 2009 at participating facilities. Data were collected through 
face-to-face interviews and medical record abstractions from June 2009 through May 2010. 
All sampled states and territories participated in MMP: California (including the separately 
funded jurisdictions of Los Angeles County and San Francisco), Delaware, Florida, Georgia, 
Illinois (including Chicago), Indiana, Michigan, Mississippi, New Jersey, New York 
(including New York City), North Carolina, Oregon, Pennsylvania (including Philadelphia), 
Puerto Rico, Texas (including Houston), Virginia, and Washington. Of 603 sampled 
facilities, 461 participated in MMP (facility response rate, 76%). Most of the HIV care 
facilities sampled were private practices [60%, 95% confidence interval (CI) 51–69], 
followed by hospital-based facilities (30%, CI 26–34) and community health centers (19%, 
CI 13–25). The remainder were clinical research facilities (10%, CI 8–13), state or local 
health department clinics (5%, CI 3–7), community-based service organizations (4%, CI 2–
6), and Veterans Administration facilities (4%, CI 2–5). A facility could belong to multiple 
categories. Of 9338 sampled persons, 4217 completed the interview and had their medical 
records abstracted (patient-level response rate, 51%), for an overall response rate of 39%. 
Data were weighted on the basis of known probabilities of selection at state or territory, 
facility, and patient levels. In addition, data were weighted to adjust for nonresponse by 
using predictors of patient-level response, including facility size, race/ethnicity, time since 
HIV diagnosis, and age group. After weighting for probability of selection and nonresponse, 
the 4217 participants in the 2009 MMP data collection cycle were estimated to represent a 
population of 421 186 HIV-infected adults receiving medical care in the United States 
during January to April 2009.
Ethics statement
The institutional review board of the Centers for Disease Control and Prevention (CDC) 
determined that MMP is a public health surveillance activity, not research. Participating 
states or territories and facilities obtained local institutional review board approval to 
conduct MMP if required locally.
Analysis of racial differences in transmission risk factors
All analyses were performed by using SAS, version 9.3 (SAS Institute, Cary, North 
Carolina, USA), and SUDAAN, version 10.0.1 (Research Triangle Institute, Research 
Triangle Park, North Carolina, USA), and accounted for clustering, unequal selection 
probabilities, and facility and patient nonresponse. Weighted estimates and percentages are 
presented. To determine the proportion of sexually active black and white MSM, we 
identified black or white MSM on the basis of self-report of black (not Hispanic) or white 
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(not Hispanic) race and self-report of oral or anal sex with a man during the past 12 months 
or, for those reporting no sexual activity, self-report of gay or bisexual sexual orientation. 
We restricted our primary analysis to sexually active MSM. Our principal goal was to test 
for differences in factors associated with HIV transmission, specifically the prevalence of 
unprotected anal sex with a male partner of negative or unknown HIV status, number of 
male oral or anal sex partners in the past 12 months, self-reported current ART use, and viral 
suppression. Using data abstracted from the participant’s medical records, we assessed two 
measures of viral suppression: current viral suppression (most recent viral load documented 
as undetectable or ≤200 copies/ml) and durable viral suppression (all viral loads in past 12 
months documented as undetectable or <400 copies/ml). The former captured HIV treatment 
success per US Department of Health and Human Services clinical guidelines [24]; the latter 
was used to assess the potential for HIV transmission during the period in which behaviors 
were assessed. We used modified Rao–Scott χ2 tests to assess differences in the transmission 
risk factors of black and white MSM.
Analysis of mediators of racial differences in transmission risk factors
After calculating the transmission risk factors (sexual behavior, ARTuse, and viral 
suppression), we performed multivariable analysis to determine which transmission risk 
factors significantly differed for black and white MSM and might explain increased risk of 
HIV transmission among black MSM (e.g. more sexual risk behavior, lower ART use, or 
lower viral suppression). To assess factors that mediated the relationship between race and 
each outcome, in our models we included variables that met the following criteria: 
associated with the outcome at P <0.10 according to modified Rao–Scott χ2 tests, and 
inclusion in the model changed the association between race and the outcome by more than 
10%. We used logistic regression models with predicted marginals to calculate the adjusted 
predicted prevalence of each outcome after adjusting for the other variables in the model. 
We then compared the unadjusted and the adjusted predicted prevalence of each outcome to 
assess how the racial difference changed with the inclusion of the other variables in the 
model.
Candidate variables for inclusion in the models were self-reported age, educational 
attainment, time since HIV diagnosis, homelessness (per the Stewart B. McKinney 
Homeless Assistance Act, 42 U.S.C. §11301, et seq; 1987), lapse in health coverage, 
household poverty [per US Health and Human Services poverty guidelines (http://
aspe.hhs.gov/poverty/figures-fed-reg.shtml)], depression in the past 2 weeks (assessed by 
using the Patient Health Questionnaire 8-item scale [25]), and HIV disease stage (AIDS 
diagnosis or lowest CD4+ T-cell count of < 200, no AIDS diagnosis and lowest CD4+ T-cell 
count of 200–499, no AIDS diagnosis and lowest CD4+ T-cell count of ≥500).
Results
Of the 4217 MMP participants with matched interview and medical record data, 445 were 
black MSM (10%; CI 8–13 or an estimated 44 142 persons, CI 35 122–53 163) and 1004 
were white MSM (25%; CI 20–30 or an estimated 105 346 persons, CI 78 542–132 149). Of 
the 445 black MSM, 314 were sexually active (69%; CI 63–75 or an estimated 30 477 
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persons, CI 24 397–36 558). Of the 1004 white MSM, 696 were sexually active (68%; CI 
65–71 or an estimated 71 823 persons, CI 52 560–91 086). Compared with sexually active 
white MSM, sexually active black MSM were significantly younger, less educated, poorer, 
more likely to have had a lapse in health coverage, and to have a more recent HIV diagnosis 
(Table 1).
Factors related to transmission risk
Sexually active black MSM were no more likely than white MSM to engage in unprotected 
sex with a male partner of negative or unknown HIV status (P =0.71) or to do so while not 
durably virally suppressed (P =0.60; Table 1). Moreover, black MSM were less likely to 
have four or more male sex partners (P =0.01). Black MSM had significantly lower levels of 
ART use (P <0.01), current viral suppression (P <0.01), and durable viral suppression (P 
<0.01; Fig. 1). During the past 12 months, 69% of white MSM vs. 48% of black MSM had 
experienced durable viral suppression.
Mediators of racial differences in transmission risk factors
Table 2 presents the unadjusted and adjusted logistic regression models for ART use and 
durable viral suppression among those taking ART. Variables that met our criteria for 
mediating the racial disparity in ART use were age, lapse in health coverage, poverty, time 
since HIV diagnosis, and HIV disease stage. Adjusting for these covariates reduced, but did 
not eliminate, the disparity between black and white MSM in ART use. Variables that met 
our criteria for mediating the racial disparity in durable viral suppression were age, lapse in 
health coverage, poverty, education, and time since HIV diagnosis. After adjusting for these 
covariates, fewer black MSM on ART were virally suppressed compared with white MSM, 
but this difference was no longer statistically significant.
Figures 2 and 3 present, by race, the unadjusted and adjusted predicted prevalence of ART 
use and durable viral suppression among those taking ART. In the final multivariable model 
for ART use, adjusting for other factors did not change the predicted prevalence of ART use 
for white MSM (91%) but increased the predicted prevalence of ART use for black MSM 
from 80 to 84%, decreasing the risk difference by 36% (from 11 to 7 percentage points; Fig. 
2). In the final model for durable viral suppression, adjusting for other factors changed the 
predicted prevalence of durable viral suppression for white MSM from 74 to 72% and 
increased the predicted prevalence of durable viral suppression for black MSM from 58 to 
65%, reducing the racial risk difference by 56% (from 16 to 7 percentage points; Fig. 3).
Discussion
We present the first national estimates of the prevalence of sexual transmission risk 
behaviors, ART use, and viral suppression among black and white HIV-infected MSM who 
are receiving medical care in the United States. We, like other researchers [6–11], found no 
evidence of racial differences in prevalence of sexual behaviors that increase the risk of HIV 
transmission; thus, racial differences in sexual risk behaviors among HIV-infected MSM 
who are in care do not appear to contribute to disparities in HIV incidence among MSM. 
However, black MSM were significantly less likely to take ART, and those who took ART 
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were less likely to be virally suppressed – differences that contribute to relatively poorer 
health outcomes among HIV-infected black MSM and may partially explain higher HIV 
incidence among HIV-uninfected black MSM.
Among persons receiving HIV care, the continuum of care involves two additional steps: the 
prescription of ART and viral suppression. At each step, we found evidence of disparities 
between sexually active black and white MSM. Our multivariable models suggest that both 
disease-related and sociodemographic factors contribute to these differences. HIV-infected 
black MSM were more recently diagnosed than white MSM, which may contribute to racial 
differences in ART use and viral suppression because recent diagnosis is associated with 
decreased engagement in care [26], which can result in suboptimal treatment and health 
outcomes [27–30]. Therefore, implementing robust early linkage and retention to care 
programs specifically for black MSM with a recent diagnosis may help to reduce disparities 
in HIV incidence. Additionally, HIV-infected black MSM as a group are younger than white 
MSM, and younger persons have been shown to be less likely to engage in care, adhere to 
ART, and achieve viral suppression [31,32]. This difference in age distribution partially 
contributes to the racial disparity in ARTuse and viral suppression and highlights the need 
for the delivery of youth-centered care for MSM, especially black MSM.
We used a social determinant of health framework [33] to illustrate our findings about the 
mechanisms through which differences in access to health resources contribute to racial 
disparities. We found that the lower levels of continuous health coverage, higher poverty, 
and lower education of black MSM partially explained the racial difference in ART use and 
subsequent viral suppression. The Affordable Care Act offers an opportunity to address 
inequities in healthcare access that may improve health outcomes and potentially decrease 
disparities in HIV incidence among black and white MSM through the provision of 
continual health coverage and access to high-quality care [34]. Through their positive effect 
on health and health promoting behaviors, improvements in income and education through 
job training and community development programs [35–37] may also help to decrease racial 
disparities in HIV infection and health outcomes among MSM. The disproportionate burden 
of poverty and low education among HIV-infected black MSM highlights the need to design 
care models that accommodate the subsistence needs of black MSM and address poor health 
literacy and numeracy in this population.
However, even after we adjusted for these other factors, black MSM were still less likely 
than white MSM to take ART. Another possible contributor to racial differences in ART use 
is variation in provider prescribing practices, which may be influenced by providers’ 
perceptions of a patient’s likelihood of adherence [38,39] or by limited resources for 
medications at the patient, facility, or community levels [39–41]. Other possible reasons for 
differences in ART use may be related to racial disparities in acceptance of ART, which are 
influenced by negative healthcare beliefs [42–44], stigma [45], and the differential impact of 
homophobia in black vs. white communities [46]. Understanding these factors is crucial for 
developing interventions that increase ART use among black MSM.
In addition, our multivariable model showed that black MSM taking ART were less likely 
than white MSM taking ART to achieve durable viral suppression. This finding might be 
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partially explained by lower ART adherence by black MSM [9,47]. Racial differences in 
health literacy and medication management have been found to mediate the relationship 
between black race and poor ART adherence [48,49], but the effect of health literacy and 
medication management on adherence among black MSM needs further exploration. Black 
MSM who do not adhere to ART or have treatment interruptions might also be at increased 
risk of antiretroviral resistance, which may limit treatment options.
Our analysis is subject to several limitations. First, the study population was limited to those 
in medical care. Racial disparities in the entire HIV-infected MSM population are likely 
greater than those presented in this analysis, because blacks are less likely than whites to be 
aware of their infection, linked to care, and retained in care [9,50,51]. Second, self-reported 
information may have led to measurement bias, although we have no reason to believe that 
this bias would differ by race. Third, although we found no differences in our measures of 
sexual behaviors that could explain higher HIV incidence among black MSM, we did not 
assess other factors that might increase the risk of sexual transmission of HIV, such as 
sexual network characteristics, sexually transmitted disease prevalence, or frequency of sex 
acts. Also, MMP does not collect information on the race of the participant’s sex partners. 
However, black MSM are likely to have black males as sex partners [2–5], although this 
may vary by geographic area and the demographics of the local population. Fourth, our 
analysis only addresses factors that affect HIV transmissions from black and white MSM 
who are aware of their HIV diagnosis and receiving medical care, a subset of the HIV-
infected population. In addition, we were unable to assess other factors that may affect the 
likelihood of HIV transmission, such as partner or HIV viral characteristics. Because 
persons who are unaware of their infection are estimated to account for a large proportion of 
HIV transmissions [52] and those not receiving medical care are less likely to be virally 
suppressed, our recommendations should be viewed as components of the more 
comprehensive efforts that are needed to decrease HIV transmission and reduce racial 
disparities in HIV acquisition. However, engagement in medical care is dynamic [53]; thus, 
there is a need to direct prevention efforts to those in and out of care. Finally, our combined 
response rate was lower than optimal, but even with low response there is tremendous value 
in unbiased sampling from rigorously constructed frames [54]. Moreover, we have assessed 
and adjusted for nonresponse using widely accepted statistical techniques, although we 
acknowledge the possibility of residual nonresponse bias.
In conclusion, we found that most HIV-infected MSM in medical care in the United States 
were taking ART and were virally suppressed, but black MSM, compared with white MSM, 
were significantly less likely to use ART and achieve viral suppression. Some estimates 
suggest that as many as one-half of black MSM will be HIV infected at age 35 [12], and our 
analysis suggests that if current trends continue, many of these men will not achieve durable 
viral suppression. Although we cannot change the current HIV prevalence in the black MSM 
community, we can make efforts to ensure that all HIV-infected black MSM achieve viral 
suppression, which would improve their health and could lower the likelihood of HIV 
transmission to their partners. In addition to increasing the numbers of HIV-infected black 
MSM who are diagnosed and engaged in medical care, our analysis suggests that, to 
accomplish this we need to make efforts to increase ART use among black MSM and 
address the structural inequalities between black and white MSM. Although further studies 
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are needed to fully explain disparities in ART use and subsequent viral suppression among 
MSM, our results suggest several areas of focus that may help reduce HIV incidence among 
black MSM: aggressive early linkage and retention programs, youth-focused delivery of 
care, and programs that increase access to resources – such as healthcare, income, and 
education – that promote health.
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Fig. 1. Antiretroviral therapy use and recent and durable viral suppression among black and 
white HIV-infected sexually active MSM receiving medical care – Medical Monitoring Project, 
United States, 2009
Recent viral suppression: most recent viral load documented ≤200 or undetectable; durable 
viral suppression: all viral loads past year documented less than 400 or undetectable; all 
black/white differences significant at P < 0.01. *95% confidence limits.
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Fig. 2. Antiretroviral therapy use among black and white HIV-infected sexually active MSM 
receiving medical care – Medical Monitoring Project, United States, 2009
*Adjusted for age, lapse in health coverage, poverty, time since diagnosis, and disease stage.
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Fig. 3. Durable viral suppression among black and white HIV-infected sexually active MSM 
receiving medical care – Medical Monitoring Project, United States, 2009
^Adjusted for age, lapse in health coverage, poverty, time since diagnosis, and education.
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